Acetyl-TP53 (K372) Antibody

What is the biological significance of p53 acetylation at lysine 372?

p53 acetylation at lysine 372 (K372) plays a crucial role in regulating p53 transcriptional activity and stability. Acetylation at this site occurs in the C-terminal regulatory domain of p53 and contributes to an open conformation of p53 by inhibiting the ability of its C-terminus to bind and occlude the DNA binding domain, thereby enhancing p53 transcriptional activity . This specific modification is evolutionarily conserved across species and is induced by various forms of DNA damage, suggesting its importance in regulating cell fate in response to genotoxic stress . Additionally, K372 acetylation works in concert with other post-translational modifications, particularly methylation, to fine-tune p53's function as a transcription factor and tumor suppressor .

How does p53 K372 acetylation differ from acetylation at other lysine residues?

p53 acetylation occurs at multiple sites, including six C-terminal lysines (K370, K372, K373, K381, K382, K386) and two lysines in the DNA-binding domain (K120, K164). While all these modifications contribute to p53 activation, they do so through different mechanisms:

K372 acetylation has a unique relationship with methylation, where methylation at K372 by Set7/9 can stimulate subsequent acetylation, enhancing p53 stability and activity . This interplay between methylation and acetylation represents a complex regulatory mechanism specific to this residue that is not observed at other acetylation sites .

What controls should be included when using Acetyl-TP53 (K372) antibodies in Western blotting experiments?

When designing Western blotting experiments with Acetyl-TP53 (K372) antibodies, the following controls are essential:

• Positive control: Lysates from cells treated with DNA-damaging agents (e.g., adriamycin, actinomycin D) to induce p53 acetylation .

• Negative controls:

  • Non-acetylated p53 peptide or recombinant protein

  • Lysates from p53-null cells (e.g., H1299)

  • Lysates from cells treated with deacetylase inhibitors followed by acetylation inhibitors

• Specificity controls:

  • Peptide competition assay using the immunizing peptide that contains acetylated K372

  • Parallel blotting with total p53 antibody to normalize for p53 protein levels

  • K372R mutant p53 (lysine to arginine) that cannot be acetylated at this position

• Treatment validation:

  • Histone deacetylase inhibitors (e.g., trichostatin A, nicotinamide) to increase acetylation levels

  • DNA damage inducers with time-course analysis to monitor acetylation dynamics

These controls ensure that the observed signal is specific to acetylated p53 at K372 and not due to cross-reactivity with other acetylated lysines or proteins.

How should researchers optimize immunoprecipitation protocols for detecting p53 K372 acetylation?

Optimizing immunoprecipitation (IP) of acetylated p53 at K372 requires careful consideration of several factors:

• Lysis buffer composition:

  • Include deacetylase inhibitors (5-10 mM nicotinamide, 1-5 μM trichostatin A)

  • Add protease inhibitors and phosphatase inhibitors

  • Use gentle detergents (0.5-1% NP-40 or Triton X-100) to preserve protein interactions

  • Consider adding 10-20 mM β-glycerophosphate to inhibit phosphatases

• Pre-clearing step:

  • Pre-clear lysates with protein A/G beads for 1 hour at 4°C to reduce non-specific binding

• Antibody amount and incubation:

  • Use 2-5 μg of purified Acetyl-p53 (K372) antibody per 1-1.5 mg of whole-cell extract

  • Incubate overnight (16 hours) at 4°C with gentle rotation

• Washing conditions:

  • Perform 4-5 washes with increasing stringency

  • Final wash with PBS containing 0.1% NP-40

  • Avoid harsh washing conditions that might disrupt the antibody-antigen interaction

• Elution methods:

  • Competitive elution with excess acetylated peptide is preferable for maintaining the native state of the protein

  • Alternative: elute with SDS sample buffer (100 mM Na₂HPO₄, 150 mM NaCl, 2 mM EDTA, 5 mM DTT, 1% Triton X-100, 3% SDS)

• Detection method:

  • Western blot with total p53 antibody to detect the immunoprecipitated acetylated p53

  • Consider mass spectrometry for confirmation of acetylation at K372

This optimized protocol increases the specificity and sensitivity of detecting K372-acetylated p53 in complex cellular lysates.

How can researchers use Acetyl-TP53 (K372) antibodies to investigate the interplay between p53 methylation and acetylation?

The interplay between p53 methylation and acetylation at K372 represents a complex regulatory mechanism that can be investigated using the following methodological approach:

• Sequential modification analysis:

  • Perform methylation assays with recombinant Set7/9 and p53 peptides, followed by acetylation assays with p300/CBP

  • Use radioactive SAM and acetyl-CoA to quantify the degree of modifications

  • Compare modification rates of unmethylated vs. methylated p53 peptides

• Chromatin immunoprecipitation (ChIP) sequential analysis:

  • Perform ChIP with methylation-specific antibody (mono-methyl K372)

  • Re-ChIP the same material with Acetyl-p53 (K372) antibody

  • Quantify the overlap between methylated and acetylated p53 at target gene promoters

• Mass spectrometry approaches:

  • Use high-resolution mass spectrometry to identify peptides with both modifications

  • Quantify the relative abundance of unmodified, singly modified, and doubly modified peptides

  • Map the temporal sequence of these modifications after DNA damage

• Genetic approaches:

  • Generate Set7/9 knockdown/knockout cells and examine K372 acetylation levels

  • Create K372R mutant p53 to abolish both methylation and acetylation

  • Use deacetylase inhibitors in Set7/9-deficient cells to test if forced acetylation can bypass the need for methylation

• In vitro competition assays:

  • Test whether acetylation at K372 affects subsequent methylation and vice versa

  • Use differentially modified p53 peptides to examine binding preferences of reader proteins

This methodological framework enables researchers to dissect the sequential and potentially interdependent nature of these modifications in regulating p53 function .

What are the methodological approaches to study the relationship between p53 K372 acetylation and its interaction with chromatin remodeling complexes?

Investigating the relationship between p53 K372 acetylation and chromatin remodeling complexes requires sophisticated methodological approaches:

• In vitro binding assays:

  • Synthesize peptides representing acetylated and unacetylated p53 at K372

  • Perform pull-down assays with recombinant bromodomain-containing proteins from chromatin remodeling complexes

  • Quantify binding affinities using isothermal titration calorimetry or surface plasmon resonance

• Proximity-based labeling techniques:

  • Express BioID or APEX2 fusions of p53 with K372R or wild-type

  • Compare the proximity interactome to identify acetylation-dependent interactions

  • Validate key interactions with co-immunoprecipitation using Acetyl-p53 (K372) antibody

• ChIP-sequencing approaches:

  • Perform ChIP-seq with Acetyl-p53 (K372) antibody

  • Parallel ChIP-seq for components of SWI/SNF or other chromatin remodeling complexes

  • Analyze co-occupancy genome-wide at p53 target genes

  • Compare chromatin accessibility (ATAC-seq) at sites with acetylated vs. non-acetylated p53

• Domain-specific mutations:

  • Generate mutations in bromodomains of chromatin remodelers (such as PBRM1 BD4 )

  • Test binding to acetylated p53 at K372 using co-IP with Acetyl-p53 (K372) antibody

  • Assess functional consequences on p53 target gene expression

• Real-time tracking of interactions:

  • Implement live-cell imaging with split fluorescent proteins

  • Compare wild-type p53 vs. K372R interaction dynamics with chromatin remodeling components

  • Use FRAP (Fluorescence Recovery After Photobleaching) to assess mobility differences

These approaches provide complementary data on how K372 acetylation may serve as a recognition site for bromodomain-containing chromatin remodelers, thereby influencing p53's ability to regulate transcription .

What factors can affect the specificity of Acetyl-TP53 (K372) antibodies in immunodetection applications?

Several factors can influence the specificity of Acetyl-TP53 (K372) antibodies:

• Cross-reactivity with other acetylated lysines:

  • p53 contains multiple acetylation sites with similar surrounding sequences

  • The antibody may detect p53 acetylated at K370, K373, or K382 due to sequence similarity

  • Solution: Perform peptide competition assays with acetylated peptides for each site

• Double modifications:

  • Methylation at K372 may occur simultaneously with or prior to acetylation

  • Some Acetyl-K372 antibodies may have reduced binding when adjacent residues are modified

  • Solution: Test antibody recognition using synthetically modified peptides with various combinatorial modifications

• Fixation effects in immunohistochemistry:

  • Formaldehyde fixation can create methylene bridges that mask epitopes

  • Acetyl-lysine modifications may be partially lost during fixation

  • Solution: Optimize antigen retrieval methods (citrate buffer pH 6.0, high temperature)

• Antibody batch variation:

  • Polyclonal antibodies show batch-to-batch variation

  • Solution: Validate each new lot against known positive controls

• Deacetylase activity in samples:

  • Endogenous deacetylases can remove acetylation during sample preparation

  • Solution: Always use deacetylase inhibitors (TSA for HDACs, nicotinamide for sirtuins) in lysis buffers

• p53 conformation changes:

  • Acetylation at K372 may induce conformational changes affecting epitope accessibility

  • Solution: Use denaturing conditions for Western blot and optimize native conditions for IP

Understanding these factors allows researchers to implement appropriate controls and optimization strategies to ensure reliable detection of K372-acetylated p53.

How can researchers validate the specificity of Acetyl-TP53 (K372) antibody signal in experimental systems?

Rigorous validation of Acetyl-TP53 (K372) antibody specificity requires multiple complementary approaches:

• Genetic validation:

  • Express p53 K372R mutant (cannot be acetylated at this position)

  • Compare antibody recognition between wild-type and mutant p53

  • Expected result: Signal should be present with wild-type p53 but absent with K372R mutant

• Pharmacological validation:

  • Treat cells with histone deacetylase inhibitors to increase acetylation levels

  • Treat cells with p300/CBP inhibitors to decrease acetylation

  • Expected result: Signal should increase with deacetylase inhibitors and decrease with acetyltransferase inhibitors

• Peptide competition assay:

  • Pre-incubate antibody with acetylated K372 peptide before immunodetection

  • Use unacetylated K372 peptide and irrelevant acetylated peptides as controls

  • Expected result: Only the acetylated K372 peptide should block the signal

• Immunoprecipitation-mass spectrometry:

  • Perform IP with the Acetyl-K372 antibody

  • Analyze the precipitated material by mass spectrometry

  • Expected result: Confirmation of K372 acetylation in the precipitated p53

• Correlation with acetylation-inducing conditions:

  • Monitor K372 acetylation during DNA damage response using established time points

  • Compare with other known p53 modifications

  • Expected result: Pattern should match the known temporal dynamics of p53 activation

• siRNA against acetyltransferases:

  • Knock down p300/CBP using siRNA

  • Monitor K372 acetylation levels

  • Expected result: Reduced signal intensity with acetyltransferase knockdown

These validation methods ensure that the observed signal truly represents acetylated p53 at K372 rather than experimental artifacts or cross-reactivity.

How can Acetyl-TP53 (K372) antibodies be used to investigate the temporal dynamics of p53 modifications after DNA damage?

To investigate the temporal dynamics of p53 modifications using Acetyl-TP53 (K372) antibodies, researchers can implement the following methodological approach:

• Time-course analysis with multiple modification-specific antibodies:

  • Treat cells with DNA-damaging agents (e.g., adriamycin, actinomycin D)

  • Collect samples at defined intervals (0, 1, 2, 4, 8, 12, 24 hours)

  • Perform western blots with antibodies against:

    • Acetyl-p53 (K372)

    • Methyl-p53 (K372)

    • Phospho-p53 (Ser15, Ser20)

    • Total p53

  • Quantify relative levels of each modification normalized to total p53

• Sequential ChIP (ChIP-reChIP) at different time points:

  • Perform initial ChIP with total p53 antibody

  • Split the material and perform secondary ChIP with modification-specific antibodies

  • Analyze occupancy at p53 target promoters (p21, MDM2, BAX)

  • Compare the temporal pattern of different modifications at the same genomic locations

• Live-cell imaging of modification dynamics:

  • Use modification-specific intrabodies fused to fluorescent proteins

  • Monitor real-time changes in modification patterns after DNA damage

  • Correlate with p53 nuclear accumulation and target gene activation

• Mass spectrometry-based temporal analysis:

  • Immunoprecipitate p53 at different time points after DNA damage

  • Perform high-resolution mass spectrometry

  • Quantify the relative abundance of different post-translational modifications

  • Create temporal maps of modification patterns

Research has shown that p53 acetylation at K372 often occurs after initial phosphorylation events but before or concurrent with the induction of target genes like p21 . This methodological framework allows researchers to establish the precise sequence of p53 modifications that occur during the DNA damage response and identify potential hierarchical relationships between them.

How do different forms of cellular stress affect the pattern of p53 K372 acetylation compared to other post-translational modifications?

Different cellular stressors may induce distinct patterns of p53 modifications, including K372 acetylation. The following methodological approach allows researchers to investigate these stress-specific patterns:

• Comparative stress induction:

  • Expose cells to different stressors:

    • DNA damage (UV, ionizing radiation, chemical agents)

    • Hypoxia

    • Oncogene activation

    • Metabolic stress

    • Ribosomal stress

  • Monitor K372 acetylation alongside other modifications

  • Compare modification patterns within the same cell type across stressors

• Quantitative multiplexed western blotting:

  • Use multiplexed detection systems (fluorescent secondary antibodies)

  • Probe single membranes with multiple modification-specific antibodies

  • Quantify the relative levels of each modification normalized to total p53

  • Generate stress-specific "modification signatures"

• ChIP-seq analysis across stress conditions:

  • Perform ChIP-seq with Acetyl-p53 (K372) antibody under different stress conditions

  • Compare genome-wide binding patterns

  • Identify stress-specific target genes where K372 acetylation is differentially enriched

• Mechanistic investigation of stress-specific acetyltransferase recruitment:

  • Monitor subcellular localization and activation of p300/CBP under different stresses

  • Perform co-IP between p53 and acetyltransferases across stress conditions

  • Use acetylation inhibitors to test the functional consequences of K372 acetylation in each stress context

• Correlation with biological outcomes:

  • Monitor cell fate decisions (cell cycle arrest, senescence, apoptosis) under each stress condition

  • Correlate with patterns of p53 acetylation at K372

  • Determine if K372 acetylation correlates with specific transcriptional programs or cell fate decisions

Research indicates that while DNA damage strongly induces p53 K372 acetylation, other stressors may induce different patterns, with K372 acetylation potentially contributing to stress-specific transcriptional responses . This approach allows researchers to determine whether K372 acetylation serves as a general activation mark or contributes to stress-specific responses.

What are the optimal conditions for using Acetyl-TP53 (K372) antibodies in chromatin immunoprecipitation (ChIP) experiments?

Optimizing ChIP protocols for Acetyl-TP53 (K372) antibodies requires attention to several critical parameters:

• Crosslinking optimization:

  • Use 1% formaldehyde for 10 minutes at room temperature

  • Consider dual crosslinking with EGS (ethylene glycol bis-succinimidyl succinate) before formaldehyde for improved protein-protein fixation

  • Quench with 125 mM glycine for 5 minutes

• Chromatin preparation:

  • Sonicate to achieve fragments of 200-500 bp

  • Verify fragment size by agarose gel electrophoresis

  • Include deacetylase inhibitors in all buffers (5-10 mM nicotinamide, 1 μM TSA)

• Pre-clearing and blocking:

  • Pre-clear chromatin with protein A/G beads for 1-2 hours

  • Include 1% BSA and 100 μg/ml sheared salmon sperm DNA in blocking solution

• Antibody amount and incubation:

  • Use 3-5 μg of Acetyl-p53 (K372) antibody per ChIP reaction

  • Incubate overnight at 4°C with rotation

  • Include IgG control and total p53 antibody in parallel reactions

• Washing conditions:

  • Low salt wash buffer (150 mM NaCl)

  • High salt wash buffer (500 mM NaCl)

  • LiCl wash buffer (250 mM LiCl)

  • TE buffer wash

  • Perform 4-5 washes with each buffer

• Elution and reversal of crosslinking:

  • Elute with 1% SDS, 0.1 M NaHCO₃ at 65°C

  • Reverse crosslinks overnight at 65°C

  • Treat with RNase A and Proteinase K

• DNA purification and analysis:

  • Purify DNA using phenol-chloroform extraction or commercial kits

  • Analyze by qPCR targeting p53-responsive elements in genes like p21/CDKN1A, MDM2, and BAX

• Data normalization:

  • Normalize to input DNA (typically 1-5%)

  • Compare with total p53 ChIP to determine the proportion of p53 that is acetylated at K372

  • Use IgG control to establish background signal

This optimized protocol enables reliable detection of K372-acetylated p53 at target gene promoters, allowing researchers to investigate the role of this modification in regulating transcription of specific p53 target genes .

How can researchers combine Acetyl-TP53 (K372) antibodies with other methodologies to study the functional impact of p53 acetylation?

Integrating Acetyl-TP53 (K372) antibodies with complementary methodologies provides a comprehensive understanding of the functional significance of p53 acetylation:

• ChIP-seq combined with RNA-seq:

  • Perform ChIP-seq with Acetyl-p53 (K372) antibody

  • Conduct parallel RNA-seq under the same conditions

  • Correlate K372 acetylation at promoters with gene expression changes

  • Compare with ChIP-seq using antibodies against other p53 modifications

• CRISPR-based approaches:

  • Generate K372R knock-in mutations using CRISPR-Cas9

  • Create acetyltransferase (p300/CBP) knockout or catalytic mutants

  • Compare transcriptional responses to DNA damage

  • Rescue experiments with wild-type vs. mutant p53 or acetyltransferases

• Proteomics-based interactome analysis:

  • Immunoprecipitate K372-acetylated p53 followed by mass spectrometry

  • Compare interactomes of unmodified vs. acetylated p53

  • Identify reader proteins that specifically recognize K372 acetylation

  • Validate interactions using reciprocal co-IP and proximity ligation assays

• Functional genomics screens:

  • Conduct CRISPR screens to identify genes affecting K372 acetylation

  • Screen for factors that modulate p53 target gene expression in a K372-dependent manner

  • Integrate data to build regulatory networks centered on K372 acetylation

• Single-cell approaches:

  • Implement multiplexed immunofluorescence for K372-acetylated p53 and p53 target proteins

  • Analyze cell-to-cell variation in modification patterns

  • Correlate with cell fate decisions at the single-cell level

• In vivo significance:

  • Generate mouse models with K372R mutation

  • Compare tumor susceptibility and DNA damage responses

  • Analyze tissue-specific differences in p53 acetylation patterns

This integrated approach allows researchers to move beyond correlation to establish causal relationships between K372 acetylation and specific biological outcomes, such as cell cycle arrest, senescence, or apoptosis .

What is known about the interplay between acetylation at K372 and other p53 post-translational modifications?

The interplay between p53 acetylation at K372 and other post-translational modifications forms a complex regulatory network:

Research findings indicate that:

This complex interplay creates a "modification code" that fine-tunes p53 activity in response to various stressors and cellular contexts .

How does K372 acetylation affect p53 conformational changes and DNA binding properties?

K372 acetylation induces specific conformational changes in p53 that alter its DNA binding properties through several mechanisms:

• Relief of C-terminal inhibition:

  • Unmodified C-terminus of p53 can fold back and interact with the DNA-binding domain, inhibiting DNA binding

  • K372 acetylation disrupts this interaction, promoting an "open" conformation

  • This enhances sequence-specific DNA binding to p53 response elements

• Effect on tetramerization:

  • p53 functions optimally as a tetramer

  • K372 acetylation may influence tetramer stability or assembly kinetics

  • This affects cooperative binding to DNA, particularly at low-affinity binding sites

• Allosteric effects on DNA-binding domain:

  • Acetylation in the C-terminus can induce allosteric changes in the central DNA-binding domain

  • These conformational changes may alter the specificity or strength of DNA binding

  • Different target genes may be affected to varying degrees

• Impact on binding kinetics:

  • K372 acetylation can affect both association and dissociation rates with DNA

  • This influences the residence time of p53 at different promoters

  • Longer residence times typically correlate with stronger transcriptional activation

• Promoter selectivity:

  • Acetylation patterns, including K372, contribute to differential binding to pro-arrest vs. pro-apoptotic gene promoters

  • This contributes to cell fate decisions following p53 activation

  • For example, studies suggest acetylation may favor binding to high-affinity sites in pro-arrest genes like p21 over lower-affinity sites in pro-apoptotic genes

The effects of K372 acetylation are not isolated but work in concert with other modifications to fine-tune p53's interaction with different target gene promoters, coactivators, and repressors .

What are the most recent findings regarding the role of K372 acetylation in regulating p53-dependent cell fate decisions?

Recent research has revealed nuanced roles for K372 acetylation in regulating cell fate decisions:

• Cell type-specific effects:

  • The impact of K372 acetylation varies between cell types

  • In some cells, it primarily supports cell cycle arrest programs

  • In others, it may facilitate apoptotic responses

  • This cell type specificity may relate to the presence of different cofactors or chromatin environments

• Threshold effects in p53 regulation:

  • Recent studies suggest a model where progressive accumulation of acetylation marks, including at K372, creates thresholds for different cell fate decisions

  • Low levels of acetylation may favor cell cycle arrest

  • Higher levels or specific combinations of acetylation sites may trigger apoptosis

  • K372 acetylation appears to be part of this graduated response system

• Interplay with chromatin remodelers:

  • Emerging evidence indicates that K372 acetylation, along with K382 acetylation, may serve as recognition sites for bromodomain-containing proteins in chromatin remodeling complexes

  • Recent findings with PBRM1 (a component of the PBAF complex) suggest that reader proteins for acetylated p53 may influence target gene selection

  • This creates a direct link between p53 acetylation and chromatin remodeling at target genes

• Integration with metabolic signaling:

  • New research suggests K372 acetylation may be sensitive to cellular metabolic state

  • NAD+-dependent deacetylases (sirtuins) can remove this modification

  • This creates a potential link between cellular energy status and p53 activity

  • Metabolic stress may therefore influence p53 function through changes in acetylation patterns

• Therapeutic implications:

  • Recent studies are exploring whether modulating p53 acetylation, including at K372, could enhance cancer therapy

  • Small molecules that promote acetylation or inhibit deacetylation might sensitize cells to DNA-damaging agents

  • The site-specific nature of acetylation effects offers potential for targeted interventions

These recent advances suggest that K372 acetylation is part of a complex, context-dependent regulatory system that fine-tunes p53 responses rather than functioning as a simple on/off switch .

What methodological advances are improving our ability to study site-specific p53 acetylation in more physiologically relevant contexts?

Recent methodological advances have enhanced our ability to study site-specific p53 acetylation in physiologically relevant contexts:

• Genetic models with improved physiological relevance:

  • CRISPR-engineered cell lines with endogenous p53 K372R mutations

  • Knock-in mouse models with site-specific acetylation mutants

  • Patient-derived organoids for studying acetylation in human disease contexts

  • These systems overcome limitations of overexpression models

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize modification-specific p53 localization

  • FRET-based sensors to detect acetylation in living cells

  • Multiplexed imaging to simultaneously track multiple modifications

  • These approaches provide spatial and temporal information about acetylation dynamics

• Single-cell technologies:

  • Single-cell proteomics to detect modification heterogeneity

  • CyTOF (mass cytometry) with modification-specific antibodies

  • Single-cell multi-omics to correlate acetylation with transcriptional outcomes

  • These methods reveal cell-to-cell variation in acetylation patterns

• Advanced mass spectrometry:

  • Targeted parallel reaction monitoring for precise quantification

  • Top-down proteomics to analyze intact p53 with multiple modifications

  • Crosslinking mass spectrometry to detect conformational changes induced by acetylation

  • These techniques provide more comprehensive modification profiling

• In situ analysis methods:

  • Proximity ligation assays to detect modified p53 interactions with partners

  • CODEX (CO-Detection by indEXing) for highly multiplexed tissue imaging

  • Spatial transcriptomics combined with protein modification detection

  • These approaches preserve tissue context while detecting modifications

• Acetylation site-specific genomic methods:

  • CUT&RUN or CUT&Tag with acetylation-specific antibodies for improved sensitivity

  • HiChIP to connect acetylated p53 binding with 3D genome organization

  • Long-read sequencing combined with ChIP to analyze complex regulatory regions

  • These techniques provide higher resolution genomic binding data

These methodological advances are enabling researchers to study K372 acetylation in increasingly physiological contexts, moving beyond cell lines to primary tissues, organoids, and in vivo models with endogenous p53 regulation .